The therapeutic agent may be, for example, an antisense ODN or small inhibitory RNA (siRNA) compound targeted to clusterin.

Addition of antisense TRPM-2 ODN to prostatic tumor cells in vivo is effective for delaying the onset of androgen independence.

An ODN directed to complement any region of the above-mentioned antisense transcript and the use thereof for diagnostic or therapeutic purposes.

The invention consists of oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use.

These methods include selecting a subject with a tumor and administering a therapeutically effective amount of apopototic tumor cells conjugated to a CpG oligodexoynucleotide (ODN) to the subject.

Also, methods of using the decoy oligodeoxynucleotide.

Accordingly, the present invention also relates to the use of anti-sense oligodeoxynucleotide to fibrogenic cytokines as a scarring inhibitor.

The present invention also pertains to an antisense oligodeoxynucleotide specific for interleukin-10 mRNA having the formula 5'-TGGGTCTTGGTTCTCAGCTTGGGGCAT.

It is intended to transfection of an NF-κB decoy oligodeoxynucleotide into rat cranial nerve via the carotid artery under global brain ischemia.

Disclosed is a method for inhibiting the biological degradation of a synthetic oligodeoxynucleotide or oligodeoxynucleotide analog placed into a cell or extracellular environment.